Gene-microRNA interactions associated with antipsychotic mechanisms and the metabolic side effects of olanzapine

Psychopharmacology

Volumn 227, Issue 1, 2013, Pages 67-78

  Santarelli, Danielle M ^a,b,c   Liu, Bing ^a,b,c   Duncan, Carlotta E ^b,d,e   Beveridge, Natalie J ^a,b,c   Tooney, Paul A ^a,b,c   Schofield, Peter R ^b,d,e   Cairns, Murray J ^a,b,c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^c HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^d NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antipsychotic drugs; Clozapine; Haloperidol; MicroRNA; Olanzapine; Pharmacogenomics; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; MESSENGER RNA; MICRORNA; OLANZAPINE;

ANIMAL TISSUE; ARTICLE; BAYES THEOREM; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INTERACTION; GENE REGULATORY NETWORK; GENE TARGETING; GENETIC ASSOCIATION; GENOME ANALYSIS; MALE; METABOLIC DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXICITY TESTING; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; FEMALE; GENE REGULATORY NETWORKS; MICE; MICE, INBRED C57BL; MICRORNAS; PROTEIN ARRAY ANALYSIS;

EID: 84876060778     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2939-y     Document Type: Article

References (55)

1. Agid O, Seeman P, Kapur S (2006) The "delayed onset" of antipsychotic action - an idea whose time has come and gone. J Psychiatry Neurosci 31:93-100
2. Arnaiz SL, Coronel MF, Boveris A (1999) Nitric oxide, superoxide, and hydrogen peroxide production in brain mitochondria after haloperidol treatment. Nitric Oxide Biol Chem Off J Nitric Oxide Soc 3:235-243
3. Arranz MJ, de Leon J (2007) Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 12:707-747
4. Beebe KL, Block T, Debattista C, Blasey C, Belanoff JK (2006) The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats. Behav Brain Res 171:225-229
5. Beveridge NJ, Cairns MJ (2012) MicroRNA dysregulation in schizophrenia. Neurobiol Dis 46:263-271
6. Beveridge NJ, Tooney PA, Carroll AP, Gardiner E, Bowden N, Scott RJ, Tran N, Dedova I, Cairns MJ (2008) Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet 17:1156-1168
7. Beveridge NJ, Gardiner E, Carroll AP, Tooney PA, Cairns MJ (2010) Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiatry 15:1-14
8. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96
9. Chen J, Lozach J, Garcia EW, Barnes B, Luo S, Mikoulitch I, Zhou L, Schroth G, Fan JB (2008) Highly sensitive and specific microRNA expression profiling using BeadArray technology. Nucleic Acids Res 36:e87
10. Chong VZ, Young LT, Mishra RK (2002) cDNA array reveals differential gene expression following chronic neuroleptic administration: implications of synapsin II in haloperidol treatment. J Neurochem 82:1533-1539
11. Dawe GS, Nagarajah R, Albert R, Casey DE, Gross KW, Ratty AK (2010) Antipsychotic drugs dose-dependently suppress the spontaneous hyperactivity of the chakragati mouse. Neuroscience 171:162-172
12. De Luca V, Mueller DJ, de Bartolomeis A, Kennedy JL (2007) Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol 10:697-704
13. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S (2005) Olanzapine for schizophrenia. Cochrane Database Syst Rev: CD001359
14. Duncan CE, Chetcuti AF, Schofield PR (2008) Coregulation of genes in the mouse brain following treatment with clozapine, haloperidol, or olanzapine implicates altered potassium channel subunit expression in the mechanism of antipsychotic drug action. Psychiatr Genet 18:226-239
15. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95:14863-14868
16. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA (2004) Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36:131-137
17. Evans RM, Barish GD, Wang YX (2004) PPARs and the complex journey to obesity. Nature Med 10:355-361
18. Fatemi SH, Reutiman TJ, Folsom TD, Bell C, Nos L, Fried P, Pearce DA, Singh S, Siderovski DP, Willard FS, Fukuda M (2006) Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology 31:1888-1899
19. Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19:92-105
20. Gardiner E, Beveridge NJ, Wu JQ, Carr V, Scott RJ, Tooney PA, Cairns MJ (2012) Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. Mol Psychiatry 17:827-840
21. Giraldez AJ, Cinalli RM, Glasner ME, Enright AJ, Thomson JM, Baskerville S, Hammond SM, Bartel DP, Schier AF (2005) MicroRNAs regulate brain morphogenesis in zebrafish. Science 308:833-838
22. Girgenti MJ, Nisenbaum LK, Bymaster F, Terwilliger R, Duman RS, Newton SS (2010) Antipsychotic-induced gene regulation in multiple brain regions. J Neurochem 113:175-187
23. Joy CB, Adams CE, Lawrie SM (2006) Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev: CD003082
24. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
25. Kapur S, Seeman P (2000) Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 25:161-166
26. Kim AH, Reimers M, Maher B, Williamson V, McMichael O, McClay JL, van den Oord EJ, Riley BP, Kendler KS, Vladimirov VI (2010) MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. Schizophr Res 124:183-191
27. Kontkanen O, Lakso M, Wong G, Castren E (2002a) Chronic antipsychotic drug treatment induces long-lasting expression of fos and jun family genes and activator protein 1 complex in the rat prefrontal cortex. Neuropsychopharmacology 27:152-162
28. Kontkanen O, Toronen P, Lakso M, Wong G, Castren E (2002b) Antipsychotic drug treatment induces differential gene expression in the rat cortex. J Neurochem 83:1043-1053
29. Krichevsky AM, King KS, Donahue CP, Khrapko K, Kosik KS (2003) A microRNA array reveals extensive regulation of microRNAs during brain development. RNA 9:1274-1281
30. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacol Off Publi Am Coll Neuropsychopharmacol 25:455-467
31. Li M, Fletcher PJ, Kapur S (2007) Time course of the antipsychotic effect and the underlying behavioral mechanisms. Neuropsychopharmacology 32:263-272
32. Liu B, Li J, Tsykin A, Liu L, Gaur AB, Goodall GJ (2009) Exploring complex miRNA-mRNA interactions with Bayesian networks by splitting-averaging strategy. BMC Bioinforma 10:408
33. MacDonald ML, Eaton ME, Dudman JT, Konradi C (2005) Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat. Biol Psychiatry 57:1041-1051
34. Meltzer HY, Sumiyoshi T (2008) Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav Brain Res 195:98-102
35. Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79-104
36. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17:1206-1227
37. Moreau MP, Bruse SE, David-Rus R, Buyske S, Brzustowicz LM (2011) Altered microRNA expression profiles in postmortem brain samples from individuals with schizophrenia and bipolar disorder. Biol Psychiatry 69:188-193
38. Mulder H, Franke B, van der Beek AA, Arends J, Wilmink FW, Egberts AC, Scheffer H (2007) The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Pharmacogenomics J 7:318-324
39. Perkins DO, Jeffries CD, Jarskog LF, Thomson JM, Woods K, Newman MA, Parker JS, Jin J, Hammond SM (2007) microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol 8:R27
40. Raedler TJ, Schreiner A, Naber D, Wiedemann K (2007) Early onset of treatment effects with oral risperidone. BMC Psychiatry 7:4
41. Reynolds GP, Kirk SL (2010) Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms. Pharmacol Ther 125:169-179
42. Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L (2006) Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry 163:1826-1829
43. Rukov JL, Shomron N (2011) MicroRNA pharmacogenomics: post-transcriptional regulation of drug response. Trends Mol Med 17:412-423
44. Saldanha AJ (2004) Java Treeview - extensible visualization of microarray data. Bioinformatics 20:3246-3248
45. Santarelli DM, Beveridge NJ, Tooney PA, Cairns MJ (2011) Upregulation of dicer and microRNA expression in the dorsolateral prefrontal cortex Brodmann area 46 in schizophrenia. Biol Psychiatry 69:180-187
46. Schreiber S, Getslev V, Backer MM, Weizman R, Pick CG (1999) The atypical neuroleptics clozapine and olanzapine differ regarding their antinociceptive mechanisms and potency. Pharmacol Biochem Behav 64:75-80
47. Seeman P, Chau-Wong M, Tedesco J, Wong K (1975) Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci USA 72:4376-4380
48. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V (2004) Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol 5:R13
49. Settle EC Jr, Ayd FJ Jr (1983) Haloperidol: a quarter century of experience. J Clin Psychiatry 44:440-448
50. Shomron N (2010) MicroRNAs and pharmacogenomics. Pharmacogenomics 11:629-632
51. Simosky JK, Stevens KE, Adler LE, Freedman R (2003) Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology 165:386-396
52. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116-5121
53. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034
54. Yadav VK, Oury F, Suda N, Liu ZW, Gao XB, Confavreux C, Klemenhagen KC, Tanaka KF, Gingrich JA, Guo XE, Tecott LH, Mann JJ, Hen R, Horvath TL, Karsenty G (2009) A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 138:976-989
55. Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, Wei Y, Damschroder-Williams P, Du J, Chen G, Manji HK (2009) Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 34:1395-1405